Prime Medicine (PRME) Focuses on Liver Franchise With $191.4M Cash Runway

Financial Performance - Prime Medicine Inc. reported a net loss of $201.1 million for the year 2025, with R&D expenses at $160.6 million, indicating a stable investment in research despite financial losses [1] - The company ended the year with $191.4 million in cash, cash equivalents, and investments, providing a financial runway into 2027 [1] Strategic Focus - The company is shifting its focus toward its in vivo liver franchise, specifically targeting Wilson Disease and Alpha-1 Antitrypsin Deficiency [2] - Prime Medicine plans to submit an IND or CTA for the Wilson Disease program in the first half of 2026, followed by a mid-2026 submission for the Alpha-1 Antitrypsin Deficiency program [2] Clinical Developments - Prime Medicine is actively engaging with the FDA to pursue an accelerated approval pathway for its CGD candidate, PM359, which has shown positive Phase 1/2 data [3] - The company intends to submit a BLA for PM359 once final alignment with the FDA is achieved, potentially making it the first Prime Edited therapy available to patients [3] Partnerships and Support - The company is progressing its Cystic Fibrosis program with support from the Cystic Fibrosis Foundation and continues its CAR-T partnership with Bristol Myers Squibb [2]